C12N 2310/316
Phosphonothioates
C12N2310/316 (Phosphonothioates) appears on 71 US grants and 117 published applications in this corpus.
Search patents in C12N- Granted patents
- 71
- Published applications
- 117
- Assignees
- 33
- Inventors
- 127
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 2 |
| 2003 | 1 | 7 |
| 2004 | 1 | 11 |
| 2005 | 0 | 6 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 2 | 0 |
| 2009 | 2 | 2 |
| 2010 | 3 | 2 |
| 2011 | 3 | 4 |
| 2012 | 1 | 8 |
| 2013 | 1 | 4 |
| 2014 | 1 | 3 |
| 2015 | 8 | 12 |
| 2016 | 3 | 2 |
| 2017 | 7 | 5 |
| 2018 | 4 | 3 |
| 2019 | 5 | 3 |
| 2020 | 0 | 5 |
| 2021 | 3 | 4 |
| 2022 | 0 | 3 |
| 2023 | 3 | 7 |
| 2024 | 2 | 11 |
| 2025 | 0 | 5 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for neuroprotection7 Apr 2026US 12,595,481 B2Disarm Therapeutics, Inc.
- Targeted inhibition using engineered oligonucleotides1 Oct 2024US 12,104,157 B2miRecule, Inc.
- Guide RNAs with chemical modification for prime editing30 Jan 2024US 11,884,915 B2Agilent Technologies, Inc.
- Targeted inhibition using engineered oligonucleotides24 Oct 2023US 11,795,459 B2miRecule, Inc.
- Selective antisense compounds and uses thereof22 Aug 2023US 11,732,261 B2Ionis Pharmaceuticals, Inc.
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Rnai formulation for inhibiting pcsk9 gene expression and use thereof20 Aug 2026US 2026/0242798 A1Mabwell (Shanghai) Bioscience Co., Ltd.
- Method for using guide rnas with chemical modifications4 Jun 2026US 2026/0152741 A1Agilent Technologies, Inc.
- Compositions and methods for the treatment of complications and disorders relating to von willebrand factor2 Apr 2026US 2026/0092283 A1Band Therapeutics, LLC
- Selective Antisense Compounds and Uses Thereof11 Dec 2025US 2025/0376683 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999
- Oligoribonucleotides and ribonucleases for cleaving RNA192US 7,695,902 B2Isis Pharmaceuticals, Inc. · 2010
- Oligoribonucleotides and ribonucleases for cleaving RNA142US 7,432,250 B2Isis Pharmaceuticals, Inc. · 2008
- Inhibition of neovascularization using vegf-specific oligonucleotides135US 5,814,620 AChildren's Medical Center Corporation · 1998